JP2017502016A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502016A5 JP2017502016A5 JP2016540574A JP2016540574A JP2017502016A5 JP 2017502016 A5 JP2017502016 A5 JP 2017502016A5 JP 2016540574 A JP2016540574 A JP 2016540574A JP 2016540574 A JP2016540574 A JP 2016540574A JP 2017502016 A5 JP2017502016 A5 JP 2017502016A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- cas number
- delta
- cancer
- intellikine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361919606P | 2013-12-20 | 2013-12-20 | |
| US61/919,606 | 2013-12-20 | ||
| PCT/US2014/071744 WO2015095838A2 (en) | 2013-12-20 | 2014-12-19 | Cancer treatments using combinations of mek type i and erk inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017502016A JP2017502016A (ja) | 2017-01-19 |
| JP2017502016A5 true JP2017502016A5 (2) | 2018-02-01 |
Family
ID=53403902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540574A Pending JP2017502016A (ja) | 2013-12-20 | 2014-12-19 | １型ｍｅｋ阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがんの処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20160310477A1 (2) |
| EP (1) | EP3082422A4 (2) |
| JP (1) | JP2017502016A (2) |
| AU (1) | AU2014368925A1 (2) |
| WO (1) | WO2015095838A2 (2) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010007419A (es) | 2008-01-04 | 2010-11-12 | Intellikine Inc | Ciertas entidades quimicas, composiciones y metodos. |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| ES2637113T3 (es) | 2011-01-10 | 2017-10-10 | Infinity Pharmaceuticals, Inc. | Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| AU2013337717B2 (en) | 2012-11-01 | 2018-10-25 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using PI3 kinase isoform modulators |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| JP6886165B2 (ja) * | 2016-02-15 | 2021-06-16 | 国立大学法人山形大学 | ガン抑制薬及び抗腫瘍剤、腫瘍再発防止剤、腫瘍発生予防剤 |
| SG11201811237WA (en) | 2016-06-24 | 2019-01-30 | Infinity Pharmaceuticals Inc | Combination therapies |
| EP3624896A4 (en) * | 2017-05-16 | 2021-03-31 | Biomed Valley Discoveries, Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER WITH ATYPICAL BRAF MUTATIONS |
| CN112402413B (zh) * | 2020-11-26 | 2022-03-08 | 重庆三峡医药高等专科学校 | 野马追倍半萜内酯b在制备抗肝癌药物中的应用及一种抗肝癌药物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1110957A1 (en) * | 1999-12-24 | 2001-06-27 | Applied Research Systems ARS Holding N.V. | Benzazole derivatives and their use as JNK modulators |
| WO2004004644A2 (en) * | 2002-07-05 | 2004-01-15 | Beth Israel Deaconess Medical Center | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| UA84930C2 (ru) * | 2004-05-14 | 2008-12-10 | Вертекс Фармасьютикалс Инкорпорейтед | Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения |
| JP2008514635A (ja) * | 2004-09-27 | 2008-05-08 | コーザン バイオサイエンシス インコーポレイテッド | 特異的キナーゼ阻害剤 |
| WO2008067069A2 (en) * | 2006-10-19 | 2008-06-05 | Oregon Health & Science University | Mitogen activated protein kinase phosphatase 4 (mkp4) and methods of use thereof |
| MY148609A (en) * | 2007-06-05 | 2013-05-15 | Merck Sharp & Dohme | Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer |
| ME01526B (me) * | 2009-02-26 | 2014-04-20 | Boehringer Ingelheim Int | Jedinjenja kao b1 antagonisti bradikinina |
| AU2010299835A1 (en) * | 2009-09-28 | 2012-04-05 | Centre National De La Recherche Scientifique | Irreversible inhibitors useful for the treatment of kinase-related pathologies |
| MY170236A (en) * | 2010-10-06 | 2019-07-11 | Glaxosmithkline Llc | Benzimidazole derivatives as pi3 kinase inhibitors |
-
2014
- 2014-12-19 AU AU2014368925A patent/AU2014368925A1/en not_active Abandoned
- 2014-12-19 WO PCT/US2014/071744 patent/WO2015095838A2/en not_active Ceased
- 2014-12-19 EP EP14871339.9A patent/EP3082422A4/en not_active Withdrawn
- 2014-12-19 US US15/105,945 patent/US20160310477A1/en not_active Abandoned
- 2014-12-19 JP JP2016540574A patent/JP2017502016A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017502016A5 (2) | ||
| JP2017502013A5 (2) | ||
| JP2017502017A5 (2) | ||
| JP2017500320A5 (2) | ||
| RU2016129287A (ru) | Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf | |
| JP2017502014A5 (2) | ||
| Neyns et al. | Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma | |
| Beuselinck et al. | Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases | |
| Nonnenmacher et al. | RIST: A potent new combination therapy for glioblastoma | |
| O’Sullivan | Overcoming endocrine resistance in hormone-receptor positive advanced breast cancer-the emerging role of CDK4/6 inhibitors | |
| Lindauer et al. | Dasatinib | |
| Budde et al. | Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received≥ 2 prior lines of therapy: pivotal results from a phase I/II study | |
| CN116036278A (zh) | 用于治疗具有非典型braf突变的癌症的组合物和方法 | |
| Wagner et al. | Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study | |
| EA201200560A1 (ru) | Специфическая терапия, использующая интегриновые лиганды для лечения рака | |
| JP2017530950A5 (2) | ||
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| NZ723271A (en) | Fused imidazole derivatives useful as ido inhibitors | |
| MX2021001807A (es) | Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma. | |
| EP4520398A3 (en) | Treatment of prostate cancer | |
| MX2013010770A (es) | Tratamiento de tumores solidos. | |
| KR20180129918A (ko) | 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법 | |
| Besse et al. | A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer | |
| JP2018519324A5 (2) | ||
| Islam et al. | Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy |